AKT1 and non-small cell lung carcinoma: In cases of drug-resistant NSCLC resulting from FGFR gene family amplification, combined inhibition of FGFR and AKT has shown efficacy in FGFR1-overexpressing osimertinib-resistant NSCLC cells (70).